Taxonomic group: bacteria / Proteobacteria (Phylum: Proteobacteria)
 
The structure was elucidated in this paper
NCBI PubMed ID: 34206211
Publication DOI: 10.3390/antibiotics10070751
Journal NLM ID: 101637404
Publisher: Basel, Switzerland: MDPI AG
Correspondence: yasmin.abozeidpharm.helwan.edu.eg
Institutions: Botany and Microbiology Department, Faculty of Science, Helwan University, Ain Helwan, Cairo 11795, Egypt, Bioinformatics Center, Faculty of Science, Helwan University, Ain Helwan, Cairo 11795, Egypt, Cytogenetics and Molecular Genetics Unit, Botany and Microbiology Department, Faculty of Science, Helwan University, Ain Helwan, Cairo 11795, Egypt, Biochemistry and Chemistry Department, Faculty of Science, Helwan University, Ain Helwan, Cairo 11795, Egypt, Biotechnology Department, Faculty of Science, Helwan University, Ain Helwan, Cairo 11795, Egypt, Cellular and Molecular Immunology Research Centre, London Metropolitan University, 166-220 Holloway Road, London N7 8DB, UK, National Heart and Lung Institute, Imperial College London, Norfolk Place, London W2 1PG, UK, Chemistry Department, Faculty of Science, Helwan University, Cairo 11795, Egyp, Department of Pharmaceutics, Faculty of Pharmacy, Helwan University, Cairo 11795, Egypt, Helwan Nanotechnology Center, Helwan University, Helwan, Cairo 11795, Egypt

COVID-19 is a pandemic disease caused by the SARS-CoV-2, which continues to cause global health and economic problems since emerging in China in late 2019. Until now, there are no standard antiviral treatments. Thus, several strategies were adopted to minimize virus transmission, such as social distancing, face covering protection and hand hygiene. Rhamnolipids are glycolipids produced formally by Pseudomonas aeruginosa and as biosurfactants, they were shown to have broad antimicrobial activity. In this study, we investigated the antimicrobial activity of rhamnolipids against selected multidrug resistant bacteria and SARS-CoV-2. Rhamnolipids were produced by growing Pseudomonas aeruginosa strain LeS3 in a new medium formulated from chicken carcass soup. The isolated rhamnolipids were characterized for their molecular composition, formulated into nano-micelles, and the antibacterial activity of the nano-micelles was demonstrated in vitro against both Gram-negative and Gram-positive drug resistant bacteria. In silico studies docking rhamnolipids to structural and non-structural proteins of SARS-CoV-2 was also performed. We demonstrated the efficient and specific interaction of rhamnolipids with the active sites of these proteins. Additionally, the computational studies suggested that rhamnolipids have membrane permeability activity. Thus, the obtained results indicate that SARS-CoV-2 could be another target of rhamnolipids and could find utility in the fight against COVID-19, a future perspective to be considered.

Pseudomonas aeruginosa, rhamnolipids, antibacterial agent, antiviral agent, COVID-19, docking studies, nano-micelles, SARS-CoV-2

Structure type: structural motif or average structure ; 673 [M+Na]+
Location inside paper: Fig. 1B, table 1, R2 (di-rhamnolipid)
Trivial name: rhamnolipid
Contained glycoepitopes: IEDB_133754,IEDB_136105,IEDB_225177,IEDB_885823
 
Methods: PCR, composition analysis, statistical analysis, LC-ESI-MS, antibacterial assay, TEM, molecular docking, nano-micelles characterization
Comments, role: one of the major lipids in the diramnolipid mixture with a relative abundance of 1.6%; the bacteria were grown in a medium supplemented with hydrophobic carbon sources.
3D data: molecular modeling
 
Related record ID(s): 10819
NCBI Taxonomy refs (TaxIDs): 287
Show glycosyltransferases
 

Convert structure to SMILES & 3D GlycoCT β-test WURCS 2.0 GLYCAM GlycoCT (external) GlycoCT XML (ext) GlydeII XML LinUCS Fragmentize Mol. weight

Simulate NMR spectra (GODDESS)

Show Sweet-II 3D model Generate 3D coords by GLYCAM

Taxonomic group: bacteria / Proteobacteria (Phylum: Proteobacteria)
 
The structure was elucidated in this paper
NCBI PubMed ID: 34206211
Publication DOI: 10.3390/antibiotics10070751
Journal NLM ID: 101637404
Publisher: Basel, Switzerland: MDPI AG
Correspondence: yasmin.abozeidpharm.helwan.edu.eg
Institutions: Botany and Microbiology Department, Faculty of Science, Helwan University, Ain Helwan, Cairo 11795, Egypt, Bioinformatics Center, Faculty of Science, Helwan University, Ain Helwan, Cairo 11795, Egypt, Cytogenetics and Molecular Genetics Unit, Botany and Microbiology Department, Faculty of Science, Helwan University, Ain Helwan, Cairo 11795, Egypt, Biochemistry and Chemistry Department, Faculty of Science, Helwan University, Ain Helwan, Cairo 11795, Egypt, Biotechnology Department, Faculty of Science, Helwan University, Ain Helwan, Cairo 11795, Egypt, Cellular and Molecular Immunology Research Centre, London Metropolitan University, 166-220 Holloway Road, London N7 8DB, UK, National Heart and Lung Institute, Imperial College London, Norfolk Place, London W2 1PG, UK, Chemistry Department, Faculty of Science, Helwan University, Cairo 11795, Egyp, Department of Pharmaceutics, Faculty of Pharmacy, Helwan University, Cairo 11795, Egypt, Helwan Nanotechnology Center, Helwan University, Helwan, Cairo 11795, Egypt

COVID-19 is a pandemic disease caused by the SARS-CoV-2, which continues to cause global health and economic problems since emerging in China in late 2019. Until now, there are no standard antiviral treatments. Thus, several strategies were adopted to minimize virus transmission, such as social distancing, face covering protection and hand hygiene. Rhamnolipids are glycolipids produced formally by Pseudomonas aeruginosa and as biosurfactants, they were shown to have broad antimicrobial activity. In this study, we investigated the antimicrobial activity of rhamnolipids against selected multidrug resistant bacteria and SARS-CoV-2. Rhamnolipids were produced by growing Pseudomonas aeruginosa strain LeS3 in a new medium formulated from chicken carcass soup. The isolated rhamnolipids were characterized for their molecular composition, formulated into nano-micelles, and the antibacterial activity of the nano-micelles was demonstrated in vitro against both Gram-negative and Gram-positive drug resistant bacteria. In silico studies docking rhamnolipids to structural and non-structural proteins of SARS-CoV-2 was also performed. We demonstrated the efficient and specific interaction of rhamnolipids with the active sites of these proteins. Additionally, the computational studies suggested that rhamnolipids have membrane permeability activity. Thus, the obtained results indicate that SARS-CoV-2 could be another target of rhamnolipids and could find utility in the fight against COVID-19, a future perspective to be considered.

Pseudomonas aeruginosa, rhamnolipids, antibacterial agent, antiviral agent, COVID-19, docking studies, nano-micelles, SARS-CoV-2

Structure type: monomer ; 325 [M+Na]+
Location inside paper: Fig. 1A, table 1, R1
Trivial name: rhamnolipid
Contained glycoepitopes: IEDB_136105,IEDB_225177,IEDB_885823
 
Methods: PCR, composition analysis, statistical analysis, LC-ESI-MS, antibacterial assay, TEM, molecular docking, nano-micelles characterization
Comments, role: mixture of major mono-rhamnolipids, where LIP = C8:2, C8:1, C10, C8, with a abundance of 29.4%, 25.2%, 13.6% and 12.8%, respectively; the bacteria were grown in a medium supplemented with hydrophobic carbon sources.
3D data: molecular modeling
 
Related record ID(s): 7864
NCBI Taxonomy refs (TaxIDs): 287
Show glycosyltransferases
 

Convert structure to SMILES & 3D GlycoCT β-test WURCS 2.0 GLYCAM GlycoCT (external) GlycoCT XML (ext) GlydeII XML LinUCS Fragmentize Mol. weight

Simulate NMR spectra (GODDESS)

Show Sweet-II 3D model Generate 3D coords by GLYCAM